Requires written agreements between pharmacy benefits managers and health carriers, revises PBM reporting and examination requirements, raises maximum administrative fines, requires notice of lowest-price drug options, and restricts steering incentives.
(New Title) relative to pharmacy benefits managers, managed care laws, notice of drug pricing options and pharmacy benefit manager business practices.
I support SB 665 because it strengthens transparency and accountability in PBM operations by requiring written agreements, expanding reporting, increasing fines for violations, and prohibiting steering patients toward PBM-owned pharmacies. These reforms close long-standing loopholes, protect consumers from opaque pricing practices, and ensure fair, auditable oversight across the prescription drug system.
Good morning, Mr. Chair and members of the committee, My name is Jebb Curelop. I live in Merrimack. I ask you to support Senate Bill 665 There’s a little-known reality in the prescription drug market: prices aren’t always what they seem. In many cases, a lower price is available — but pharmacies are not required to divulge these savings to consumers. If a consumer asks for available discounts, coupons or rebates they often will realize huge savings. The problem is that they have to ask. Without that question, consumers can unknowingly pay far more than necessary. Today the House Commerce and Consumer Affairs Committee has an opportunity to make a meaningful difference for New Hampshire families in bringing down the cost of prescription drugs by passing Senate Bill 665 sponsored by Senator Denise Ricciardi, R-Bedford. Most consumers assume their insurance guarantees the lowest prescription price. Too often, that isn’t the case. Unless you specifically ask about discounts or coupons, you may pay more than necessary — and pharmacies typically aren’t required to tell you. I experienced this firsthand. I was quoted $95 for a high blood pressure "Ezemtibe" prescription using insurance. After asking about available discounts, the price dropped to $35. Many people never think to ask — and end up overpaying as a result. Senate Bill 665 would require pharmacies to inform customers when a lower price is available. That’s not complicated policy — it’s basic transparency. At a time when families are struggling with rising costs, no one should have to guess whether they’re getting the best price on essential medication. New Hampshire has the chance to lead decreasing the cost of prescription drugs with a simple, consumer-focused reform. In closing, I recommend to all members of the committee that the next time you go to the pharmacy to pick up a prescription that you ask if there are any available discounts, rebates or coupons. It is highly likely that you will be pleasantly surprised with the savings. I urge Chairman Hunt and the committee to pass Senate Bill 665. Jebb Curelop
Position recorded without written comment.
Position recorded without written comment.
Position recorded without written comment.
Position recorded without written comment.
Position recorded without written comment.
Position recorded without written comment.
Position recorded without written comment.
Position recorded without written comment.